Navigation Links
Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Date:4/3/2008

in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; our future capital requirements; and the fact that data from preclinical studies and Phase 1 or Phase 2 cl
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
2. MiMedx Group Announces Post-split Name Change
3. Millennium Announces $200,000 Purchase Order From Greek Distributor
4. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
5. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
6. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
9. Human Pheromone Sciences Announces Quarterly and Full Year Results
10. Dragon Pharma announces 2007 full year financial results
11. Genaera Corporation Announces 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... Ala., July 29, 2015  HealthSouth ... nation,s largest providers of post-acute healthcare services, offering ... its results of operations for the second quarter ... quarter was characterized by strong volume growth in ... Adjusted EBITDA," said Jay Grinney, President and Chief ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... , July 29, 2015  Therapath Neuropathology ( ... increased partnerships with VA and Military Medical centers ... Fiber Density (ENFD) and Sweat Gland Nerve Fiber ... neuropathy ( https://therapath.com/skin ). Demonstration ... Density (ENFD) on punch skin biopsy is a ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... 2011) After Fukushima, it is now imperative to redefine ... to grave. If nuclear waste management is not thought out ... nuclear power as an energy choice, according to research that ... , published by SAGE. According to Allison Macfarlane, associate ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
... significant threat to humans, as emphasized by the recent effects ... on July 21st by the Cell Press journal Developmental ... similar and divergent strategies that different toxins use to invade ... protein derived from the castor bean plant that has raised ...
Cached Biology Technology:Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2Targeting toxin trafficking 2
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... -- The consumer products industry for innovative tech ... such as wearables, smart wallets & other smart technology are ... continues to rapidly grow.  Biometrics & Wearable Device Companies in ... Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ... GPRO ) and Baidu Inc. (NASDAQ: BIDU ) ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... DNA analysis, Illinois researchers have disproved decades of rumors and ... battle between Asian and African elephants. "What everyone thinks ... of animal sciences and member of the Institute for Genomic ... the research published in the Journal of Heredity . ...
... with a lamprey than we think, according to a new ... of transparent zebrafish addresses a fundamental evolution issue: How did ... L. McLean have found that the spinal cord circuits that ... previously thought. Vertebrate locomotion has evolved from the ...
... plants that use natural gas and a new technology to ... the greenhouse gas carbon dioxide than coal-fired power plants do, ... in Earth,s Future , a journal of the American ... also release significantly less nitrogen oxides and sulfur dioxide, which ...
Cached Biology News:War elephant myths debunked by DNA 2Spinal cord findings could help explain origins of limb control 2New study: US power plant emissions down 2
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
Weinreb Linker...
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
Request Info...
Biology Products: